

# ISO 20399:2022-12 (E)

## Biotechnology - Ancillary materials present during the production of cellular therapeutic products and gene therapy products

---

<b>Contents</b>		<b>Page</b>
Foreword .....		v
Introduction .....		vi
1	Scope .....	1
2	Normative references .....	1
3	Terms and definitions .....	1
4	Abbreviated terms .....	4
5	Strategy .....	5
5.1	Key concepts on AM .....	5
5.2	AM-related responsibilities .....	5
5.3	Qualification considerations of AM .....	6
5.4	Animal-derived components of AM .....	7
5.4.1	General .....	7
5.4.2	Key considerations in the use of animal-derived components .....	7
5.4.3	Viral inactivation .....	8
6	Evaluation criteria and risk mitigation for AM containing biological material .....	8
6.1	Evaluation criteria for AM selection .....	8
6.2	Mitigation of risk .....	10
6.2.1	Scientific approach .....	10
6.2.2	Supplier audit and questionnaires .....	11
6.2.3	Risk assessment .....	12
7	AM characteristics and quality attributes .....	12
7.1	AM components, identity and purity .....	12
7.1.1	General .....	12
7.1.2	Identity and quantity of component(s) .....	13
7.1.3	Purity and impurity .....	13
7.1.4	Lot-to-lot consistency for AMs containing proprietary components .....	13
7.2	AM storage and stability .....	14
7.2.1	General .....	14
7.2.2	Stability and storage conditions .....	14
8	AM manufacturing and biosafety .....	15
8.1	Quality management system .....	15
8.2	Manufacturing process .....	16
8.3	Container and closure systems .....	16
8.4	Animal and human-derived components .....	16
8.5	Safety to cells and humans .....	17
9	AM performance .....	17
9.1	General .....	17
9.2	Quality and testing .....	18
9.3	Qualification activity .....	18
9.4	Performance assay .....	19
9.5	Performance assay results .....	19

<b>10</b>	<b>AM documentation .....</b>	<b>19</b>
<b>10.1</b>	<b>General .....</b>	<b>19</b>
<b>10.2</b>	<b>Reporting requirements .....</b>	<b>20</b>
<b>10.3</b>	<b>Certificate of analysis .....</b>	<b>21</b>
<b>10.4</b>	<b>Additional certificates .....</b>	<b>22</b>
<b>10.4.1</b>	<b>Certificate of origin .....</b>	<b>22</b>
<b>10.4.2</b>	<b>Certificate of compliance .....</b>	<b>22</b>
<b>10.4.3</b>	<b>Certificate of irradiation .....</b>	<b>22</b>
<b>11</b>	<b>Managing changes to components .....</b>	<b>22</b>
<b>11.1</b>	<b>Impact of changes to components .....</b>	<b>22</b>
<b>11.2</b>	<b>Measures for managing changes to components .....</b>	<b>22</b>
	<b>Annex A (informative) Decision chart of AMs .....</b>	<b>24</b>
	<b>Annex B (informative) Example workflow from AM supplier to AM user .....</b>	<b>26</b>
	<b>Annex C (informative) Information on AM and materials used to produce AMs .....</b>	<b>27</b>
	<b>Annex D (informative) Considerations for the characterization of AMs .....</b>	<b>29</b>
	<b>Annex E (informative) Quality declarations for manufactured biological materials used in the manufacture of a cell-based therapeutic product .....</b>	<b>30</b>
	<b>Bibliography .....</b>	<b>31</b>